Jennewein Biotechnologie GmbH acquired by Chr. Hansen Holding A/S
Chr. Hansen Holding A/S acquired Jennewein Biotechnologie GmbH, a Germany & Global supplements brand, on Oct 12, 2020.
Transaction summary
- Target
- Jennewein Biotechnologie GmbH
- Acquirer
- Chr. Hansen Holding A/S
- Announced
- 2020-09-22
- Geography
- Germany & Global
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- 100%
- First added
- 2026-10-31
- Latest update
- 2026-10-31
Value and multiples
100% enterprise value
EUR 310M
100% enterprise value | EUR
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
Approx. $367M USD using FX date 2020-09-18 at 1.1833 EUR/USD.
EV / revenue
6.2x
Period: FY2020 2021
Basis: Public source
EV / EBITDA
-
EBITDA basis not stated
Basis: Public source
Basis
- Reported value: €310m enterprise value. Multiples use revenue of €50m (FY2020).
Source summary
Chr. Hansen acquires Jennewein Biotechnologie GmbH to enter and lead the high-growth Human Milk Oligosaccharides market
ConfirmedThe total consideration equals EUR 310 million on a debt-free basis.
Open sourceContinue your research
Related transaction comps
PrecisionBiotics Group Limited acquired by Novozymes
2020-06-25 · Estimated
View transaction → consumer healthVitabiotics acquired by Bain Capital
2026-07-24 · Confirmed
View transaction → consumer healthOpella acquired by Clayton, Dubilier & Rice
2024-10-21 · Confirmed
View transaction → consumer healthOnnit Labs, Inc. acquired by Unilever
2021-04-26 · Estimated
View transaction →